PE02.04 Variation in neutralization susceptibility of HIV-1 Indian subtype C to potent and broadly neutralizing monoclonal antibodies (bnAbs) having distinct epitope specificitiesE-posterBroadly neutralizing antibodies
PE02.05 Antibody genetic diversity with large structural variation in a South African populationE-posterBroadly neutralizing antibodies
PE02.06 Founder Env-specific IgM B cell responses during acute HIV-1 infection associate with the development of broadly neutralizing antibodiesE-posterBroadly neutralizing antibodies
PE02.07 IgG3 HIV broadly neutralizing antibodies show improved neutralization potency and phagocytosis compared to IgG1 variantsE-posterBroadly neutralizing antibodies
PE02.08 Defining the mechanism for varied neutralization potency of HIV neutralizing antibodies with identical variable regions but differing isotypeE-posterBroadly neutralizing antibodies
PE02.09 35O22 and VRC44 define a new highly glycan-dependent multidonor class of HIV-1 gp120:gp41 interface-directed bnAbsE-posterBroadly neutralizing antibodies
PE02.10 Precursor frequencies of naïve B cells targeting HIV candidate immunogensE-posterBroadly neutralizing antibodies
PE02.11 Low dose administration of unmodified 10E8v4, but not FcγR/complement dual enhanced or dual ablated 10E8v4 variants, decreases viremia in SHIV challenged macaquesE-posterBroadly neutralizing antibodies
PE02.12 Functional convergence of clonally related but genetically distinct bNAbs that target the V3-glycan epitopeE-posterBroadly neutralizing antibodies
PE02.13 Enhanced protection at the site of challenge of rhesus macaques that receive PGT121 one week prior to intravaginal challenge with SHIV-SF162P3E-posterBroadly neutralizing antibodies
seek-warrow-warrow-eseek-e91 - 100 of 444 items